Cargando…

LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats

BACKGROUND: Lung transplantation is the only effective treatment for end-stage lung diseases. Bronchiolitis obliterans, which is known as non-infectious chronic lung allograft dysfunction (CLAD) in the new classification, is the greatest threat to long-term survival after lung transplantation. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Zheng-Liang, Zhou, Zhen-Yu, Xu, Hai-Chao, Cao, Jin-Lin, Ye, Peng, Wang, Lu-Ming, Lv, Wang, Hu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445521/
https://www.ncbi.nlm.nih.gov/pubmed/28545478
http://dx.doi.org/10.1186/s13019-017-0605-5
_version_ 1783238910772510720
author Tu, Zheng-Liang
Zhou, Zhen-Yu
Xu, Hai-Chao
Cao, Jin-Lin
Ye, Peng
Wang, Lu-Ming
Lv, Wang
Hu, Jian
author_facet Tu, Zheng-Liang
Zhou, Zhen-Yu
Xu, Hai-Chao
Cao, Jin-Lin
Ye, Peng
Wang, Lu-Ming
Lv, Wang
Hu, Jian
author_sort Tu, Zheng-Liang
collection PubMed
description BACKGROUND: Lung transplantation is the only effective treatment for end-stage lung diseases. Bronchiolitis obliterans, which is known as non-infectious chronic lung allograft dysfunction (CLAD) in the new classification, is the greatest threat to long-term survival after lung transplantation. This study investigated the role of leukotriene B4 (LTB4) and montelukast in transplantation-related bronchiolitis obliterans and discussed the pathophysiological significance of LTB4 in chronic rejection. METHODS: Rats were randomly divided into an experimental group (montelukast), a positive control group (dexamethasone), and a blank control group (normal saline solution; NS). Each piece of trachea removed from a F344 rat was transplanted into a Lewis rat through a 5-mm incision at the episternum by subcutaneous embedding. The recipients were treated with gastric lavage with 3 mg/kg · d montelukast suspension, 1 mg/kg · d dexamethasone, and 1 mL/kg · d NS, respectively, in each group. On Day 28, peripheral blood was drawn to measure the white blood cell counts and plasma LTB4 levels. The donor specimens were stained by H-E and Masson, and their organizational structure and extent of fibrosis were visually assessed. The measurement data were compared using one-way analysis of variance, and the categorical data were compared using the chi-square test. A P value of less than 0.05 was considered to indicate statistical significance. RESULTS: The white blood cell counts of the montelukast, dexamethasone, and NS groups were (16.0 ± 4.2) × 10(9)/L, (19.5 ± 11.6) × 10(9)/L, and (25.8 ± 3.6) × 10(9)/L; no statistical significance was found (P = 0.101). The concentrations of LTB4 were 2230 ± 592 pg/mL, 1961 ± 922 pg/mL, and 3764 ± 1169 pg/mL, and statistical significance was found between the NS group and each of the others (P = 0.009). The percentages of tracheal occlusion were 73.6% ± 13.8%, 23.4% ± 3.2%, and 89.9% ± 11.3%, and statistical significance was found among the three groups (P = 0.000). CONCLUSIONS: The study established a model to simulate bronchiolitis obliterans after clinical lung transplantation. Oral administration of montelukast reduced plasma LTB4 levels in rats and played a preventive role against tracheal fibrosis after transplantation. This suggests that LTB4 may be involved in bronchiolitis obliterans after pulmonary transplantation. This study indicates a new direction for research into the prevention and treatment of bronchiolitis obliterans after lung transplantation.
format Online
Article
Text
id pubmed-5445521
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54455212017-05-30 LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats Tu, Zheng-Liang Zhou, Zhen-Yu Xu, Hai-Chao Cao, Jin-Lin Ye, Peng Wang, Lu-Ming Lv, Wang Hu, Jian J Cardiothorac Surg Research Article BACKGROUND: Lung transplantation is the only effective treatment for end-stage lung diseases. Bronchiolitis obliterans, which is known as non-infectious chronic lung allograft dysfunction (CLAD) in the new classification, is the greatest threat to long-term survival after lung transplantation. This study investigated the role of leukotriene B4 (LTB4) and montelukast in transplantation-related bronchiolitis obliterans and discussed the pathophysiological significance of LTB4 in chronic rejection. METHODS: Rats were randomly divided into an experimental group (montelukast), a positive control group (dexamethasone), and a blank control group (normal saline solution; NS). Each piece of trachea removed from a F344 rat was transplanted into a Lewis rat through a 5-mm incision at the episternum by subcutaneous embedding. The recipients were treated with gastric lavage with 3 mg/kg · d montelukast suspension, 1 mg/kg · d dexamethasone, and 1 mL/kg · d NS, respectively, in each group. On Day 28, peripheral blood was drawn to measure the white blood cell counts and plasma LTB4 levels. The donor specimens were stained by H-E and Masson, and their organizational structure and extent of fibrosis were visually assessed. The measurement data were compared using one-way analysis of variance, and the categorical data were compared using the chi-square test. A P value of less than 0.05 was considered to indicate statistical significance. RESULTS: The white blood cell counts of the montelukast, dexamethasone, and NS groups were (16.0 ± 4.2) × 10(9)/L, (19.5 ± 11.6) × 10(9)/L, and (25.8 ± 3.6) × 10(9)/L; no statistical significance was found (P = 0.101). The concentrations of LTB4 were 2230 ± 592 pg/mL, 1961 ± 922 pg/mL, and 3764 ± 1169 pg/mL, and statistical significance was found between the NS group and each of the others (P = 0.009). The percentages of tracheal occlusion were 73.6% ± 13.8%, 23.4% ± 3.2%, and 89.9% ± 11.3%, and statistical significance was found among the three groups (P = 0.000). CONCLUSIONS: The study established a model to simulate bronchiolitis obliterans after clinical lung transplantation. Oral administration of montelukast reduced plasma LTB4 levels in rats and played a preventive role against tracheal fibrosis after transplantation. This suggests that LTB4 may be involved in bronchiolitis obliterans after pulmonary transplantation. This study indicates a new direction for research into the prevention and treatment of bronchiolitis obliterans after lung transplantation. BioMed Central 2017-05-25 /pmc/articles/PMC5445521/ /pubmed/28545478 http://dx.doi.org/10.1186/s13019-017-0605-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tu, Zheng-Liang
Zhou, Zhen-Yu
Xu, Hai-Chao
Cao, Jin-Lin
Ye, Peng
Wang, Lu-Ming
Lv, Wang
Hu, Jian
LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title_full LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title_fullStr LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title_full_unstemmed LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title_short LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats
title_sort ltb4 and montelukast in transplantation-related bronchiolitis obliterans in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445521/
https://www.ncbi.nlm.nih.gov/pubmed/28545478
http://dx.doi.org/10.1186/s13019-017-0605-5
work_keys_str_mv AT tuzhengliang ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT zhouzhenyu ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT xuhaichao ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT caojinlin ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT yepeng ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT wangluming ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT lvwang ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats
AT hujian ltb4andmontelukastintransplantationrelatedbronchiolitisobliteransinrats